Objective
To test the hypothesis that levels of adropin, a recently discovered peptide that displays important metabolic and cardiovascular functions, are lower in obstructive sleep apnea (OSA), especially when associated with endothelial dysfunction.
Study design
Age-, sex- and ethnicity-matched children (mean age: 7.2±1.4 years) were included into one of three groups based on the presence of OSA in an overnight sleep study, and on the time to post-occlusive maximal reperfusion (Tmax>45 sec) with a modified hyperemic test. Plasma adropin levels were assayed using a commercial ELISA kit.
Results
Among controls, mean morning adropin levels were 7.4 ng/ml (95% confidence intervals: 5.2–16.3 ng/ml) OSA children with abnormal endothelial function (OSA+/EF+) had significantly lower adropin levels (2.7±1.1 ng/ml, n=35) compared with matched controls (7.6±1.4 ng/ml; n=35; p<0.001), and to children with OSA and normal endothelial function (OSA+/EF−: 5.8±1.5 ng/ml, n=47; p<0.001). Plasma adropin <4.2 ng/ml reliably predicted endothelial functional status, but individual adropin levels were not significantly correlated with age, BMI-z score, obstructive apnea-hypopnea index (AHI) or nadir SpO2. Adropin levels were assessed after adenotonsillectomy in a subset of children with OSA (n=22), and showed increases in OSA+/EF+ (2.5±1.4 ng/ml to 6.4±1.9 ng/ml, n=14; p<0.01) but remained unchanged in OSA+EF− (5.7±1.3 ng/ml to 6.4±1.1 ng/ml, n=8; p>0.05).
Conclusion
Plasma adropin levels are reduced in pediatric OSA when endothelial dysfunction is present, and return to within normal values after adenotonsillectomy. Assessment of adropin circulating levels may provide a reliable indicator of vascular injury in the context of OSA on children.